Vectors based on adeno-associated virus (AAV) are promising tools for gene therapy. The production of strongly toxic vectors, for example for cancer-directed gene transfer, is often unfeasible due to uncontrolled expression of toxic genes in vector-producing cells. Using an approach based on transcriptional repression, we have created novel AAV vectors carrying the genes coding for diphtheria toxin A (DTA) and the pro-apoptotic PUMA protein. The DTA vector had a significant toxic effect on a panel of tumor cell lines, and abrogation of protein synthesis could be shown. The PUMA vector had a toxic effect on HeLa and RPMI 8226 cells, and sensitized transduced cells to doxorubicin. To permit targeted gene transfer, we incorporated the DTA gene into a genetically modified AAV-2 capsid previously developed by our group that mediates enhanced transduction of murine breast cancer cells in vitro. This vector had a stronger cytotoxic effect on breast cancer cells than DTA vectors with wildtype AAV capsid or vectors with a random capsid modification. The vector production and application system presented here allows for easy exchange of promotors, transgenes and capsid specificity for certain target cells. It will therefore be of great possible value in a broad range of applications in cytotoxic gene therapy and significantly broadens the spectrum of available tools for AAV-based gene therapy.
Michelfelder, S.; Trepel, M. Adeno-associated viral vectors and their redirection to cell-type specific receptors. Adv. Genet.？2009, 67, 29–60. 19914449
[6]
Nicklin, S.A.; Baker, A.H. Tropism-modified adenoviral and adeno-associated viral vectors for gene therapy. Curr. Gene Ther.？2002, 2, 273–293, doi:10.2174/1566523023347797. 12189716
[7]
Wu, Z.; Asokan, A.; Samulski, R.J. Adeno-associated virus serotypes: Vector toolkit for human gene therapy. Mol.Ther.？2006, 14, 316–327, doi:10.1016/j.ymthe.2006.05.009. 16824801
[8]
Girod, A.; Ried, M.; Wobus, C.; Lahm, H.; Leike, K.; Kleinschmidt, J.; Deleage, G.; Hallek, M. Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2. Nat. Med.？1999, 5, 1052–1056, doi:10.1038/12491. 10470084
[9]
Grifman, M.; Trepel, M.; Speece, P.; Gilbert, L.B.; Arap, W.; Pasqualini, R.; Weitzman, M.D. Incorporation of tumor-targeting peptides into recombinant adeno-associated virus capsids. Mol. Ther.？2001, 3, 964–975, doi:10.1006/mthe.2001.0345. 11407911
[10]
Shi, W.; Bartlett, J.S. RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther.？2003, 7, 515–525, doi:10.1016/S1525-0016(03)00042-X. 12727115
[11]
Bartlett, J.S.; Kleinschmidt, J.; Boucher, R.C.; Samulski, R.J. Targeted adeno-associated virus vector transduction of nonpermissive cells mediated by a bispecific F(ab'gamma)2 antibody. Nat. Biotechnol.？1999, 17, 181–186, doi:10.1038/6185. 10052356
[12]
Ponnazhagan, S.; Mahendra, G.; Kumar, S.; Thompson, J.A.; Castillas, M., Jr. Conjugate-based targeting of recombinant adeno-associated virus type 2 vectors by using avidin-linked ligands. J. Virol.？2002, 76, 12900–12907, doi:10.1128/JVI.76.24.12900-12907.2002. 12438615
[13]
Trepel, M.G.; Weitzman, M.D.; Pasqualini, R. Molecular adaptors for vascular-targeted adenoviral gene delivery. Hum. Gene Ther.？2000, 11, 1971–1981, doi:10.1089/10430340050143408. 11020797
[14]
Müller, O.J.; Kaul, F.; Weitzman, M.D.; Pasqualini, R.; Arap, W.; Kleinschmidt, J.A.; Trepel, M. Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors. Nat. Biotechnol.？2003, 21, 1040–1046, doi:10.1038/nbt856. 12897791
[15]
Waterkamp, D.A.; Muller, O.J.; Ying, Y.; Trepel, M.; Kleinschmidt, J.A. Isolation of targeted AAV2 vectors from novel virus display libraries. J. Gene Med.？2006, 8, 1307–1319, doi:10.1002/jgm.967. 16955542
Michelfelder, S.; Kohlschutter, J.; Skorupa, A.; Pfennings, S.; Muller, O.; Kleinschmidt, J.A.; Trepel, M. Successful expansion but not complete restriction of tropism of adeno-associated virus by in vivo biopanning of random virus display peptide libraries. PLoS One？2009, 4, e5122, doi:10.1371/journal.pone.0005122. 19357785
[18]
Ying, Y.; Muller, O.J.; Goehringer, C.; Leuchs, B.; Trepel, M.; Katus, H.A.; Kleinschmidt, J.A. Heart-targeted adeno-associated viral vectors selected by in vivo biopanning of a random viral display peptide library. Gene Ther.？2010, 17, 980–990, doi:10.1038/gt.2010.44. 20393510
[19]
Li, C.; Bowles, D.E.; van Dyke, T.; Samulski, R.J. Adeno-associated virus vectors: Potential applications for cancer gene therapy. Canc. Gene Ther.？2005, 12, 913–925, doi:10.1038/sj.cgt.7700876.
[20]
Su, H.; Chang, J.C.; Xu, S.M.; Kan, Y.W. Selective killing of AFP-positive hepatocellular carcinoma cells by adeno-associated virus transfer of the herpes simplex virus thymidine kinase gene. Hum. Gene Ther.？1996, 7, 463–470, doi:10.1089/hum.1996.7.4-463. 8800740
[21]
Hajitou, A.; Trepel, M.; Lilley, C.E.; Soghomonyan, S.; Alauddin, M.M.; Marini, F.C., 3rd; Restel, B.H.; Ozawa, M.G.; Moya, C.A.; Rangel, R.; Sun, Y.; Zaoui, K.; Schmidt, M.; von Kalle, C.; Weitzman, M.D.; Gelovani, J.G.; Pasqualini, R.; Arap, W. A hybrid vector for ligand-directed tumor targeting and molecular imaging. Cell？2006, 125, 385–398, doi:10.1016/j.cell.2006.02.042. 16630824
[22]
Trepel, M.; Stoneham, C.A.; Eleftherohorinou, H.; Mazarakis, N.D.; Pasqualini, R.; Arap, W.; Hajitou, A. A heterotypic bystander effect for tumor cell killing after adeno-associated virus/phage-mediated, vascular-targeted suicide gene transfer. Mol. Canc. Ther.？2009, 8, 2383–2391, doi:10.1158/1535-7163.MCT-09-0110.
[23]
Wang, Y.; Huang, F.; Cai, H.; Zhong, S.; Liu, X.; Tan, W.S. Potent antitumor effect of TRAIL mediated by a novel adeno-associated viral vector targeting to telomerase activity for human hepatocellular carcinoma. J. Gene Med.？2008, 10, 518–526, doi:10.1002/jgm.1177. 18338833
[24]
Zhang, Y.; Ma, H.; Zhang, J.; Liu, S.; Liu, Y.; Zheng, D. AAV-mediated TRAIL gene expression driven by hTERT promoter suppressed human hepatocellular carcinoma growth in mice. Life Sci.？2008, 82, 1154–1161, doi:10.1016/j.lfs.2008.03.023. 18485417
[25]
Nettelbeck, D.M.; Jerome, V.; Muller, R. A strategy for enhancing the transcriptional activity of weak cell type-specific promoters. Gene Ther.？1998, 5, 1656–1664, doi:10.1038/sj.gt.3300778. 10023445
[26]
Gossen, M.; Bujard, H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc. Natl. Acad. Sci. USA？1992, 89, 5547–5551, doi:10.1073/pnas.89.12.5547. 1319065
[27]
Choe, S.; Bennett, M.J.; Fujii, G.; Curmi, P.M.; Kantardjieff, K.A.; Collier, R.J.; Eisenberg, D. The crystal structure of diphtheria toxin. Nature？1992, 357, 216–222, doi:10.1038/357216a0. 1589020
[28]
Nakano, K.; Vousden, K.H. PUMA, a novel proapoptotic gene, is induced by p53. Mol. Cell.？2001, 7, 683–694, doi:10.1016/S1097-2765(01)00214-3. 11463392
[29]
Guy, C.T.; Cardiff, R.D.; Muller, W.J. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol. Cell. Biol.？1992, 12, 954–961. 1312220
[30]
Grimm, D.; Kern, A.; Pawlita, M.; Ferrari, F.; Samulski, R.; Kleinschmidt, J. Titration of AAV-2 particles via a novel capsid ELISA: packaging of genomes can limit production of recombinant AAV-2. Gene Ther.？1999, 6, 1322–1330, doi:10.1038/sj.gt.3300946. 10455443
[31]
Lee, E.J.; Jameson, J.L. Cell-specific Cre-mediated activation of the diphtheria toxin gene in pituitary tumor cells: Potential for cytotoxic gene therapy. Hum. Gene Ther.？2002, 13, 533–542, doi:10.1089/10430340252809829. 11874631
[32]
Xiao, X.; Li, J.; Samulski, R.J. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J. Virol.？1998, 72, 2224–2232. 9499080
[33]
Hermens, W.T.; ter Brake, O.; Dijkhuizen, P.A.; Sonnemans, M.A.; Grimm, D.; Kleinschmidt, J.A.; Verhaagen, J. Purification of recombinant adeno-associated virus by iodixanol gradient ultracentrifugation allows rapid and reproducible preparation of vector stocks for gene transfer in the nervous system. Hum. Gene Ther.？1999, 10, 1885–1891, doi:10.1089/10430349950017563. 10446928
[34]
Slater, T.F.; Sawyer, B.; Straeuli, U. Studies on Succinate-Tetrazolium Reductase Systems.Iii. Points of Coupling of Four Different Tetrazolium Salts. Biochim. Biophys. Acta？1963, 77, 383–393, doi:10.1016/0006-3002(63)90513-4. 14089413
[35]
Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Method.？1983, 65, 55–63, doi:10.1016/0022-1759(83)90303-4.
[36]
Wang, H.; Qian, H.; Yu, J.; Zhang, X.; Zhang, L.; Fu, M.; Liang, X.; Zhan, Q.; Lin, C. Administration of PUMA adenovirus increases the sensitivity of esophageal cancer cells to anticancer drugs. Canc. Biol. Ther.？2006, 5, 380–385, doi:10.4161/cbt.5.4.2477.
[37]
Yu, J.; Yue, W.; Wu, B.; Zhang, L. PUMA sensitizes lung cancer cells to chemotherapeutic agents and irradiation. Clin. Canc. Res.？2006, 12, 2928–2936, doi:10.1158/1078-0432.CCR-05-2429.
[38]
Freeman, S.M.; Abboud, C.N.; Whartenby, K.A.; Packman, C.H.; Koeplin, D.S.; Moolten, F.L.; Abraham, G.N. The "bystander effect": Tumor regression when a fraction of the tumor mass is genetically modified. Canc. Res.？1993, 53, 5274–5283.
[39]
Massuda, E.S.; Dunphy, E.J.; Redman, R.A.; Schreiber, J.J.; Nauta, L.E.; Barr, F.G.; Maxwell, I.H.; Cripe, T.P. Regulated expression of the diphtheria toxin A chain by a tumor-specific chimeric transcription factor results in selective toxicity for alveolar rhabdomyosarcoma cells. Proc. Natl. Acad. Sci. USA？1997, 94, 14701–14706, doi:10.1073/pnas.94.26.14701. 9405676
[40]
Yamaizumi, M.; Mekada, E.; Uchida, T.; Okada, Y. One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell. Cell？1978, 15, 245–250, doi:10.1016/0092-8674(78)90099-5. 699044
